Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€2.88

€2.88

6.080%
0.165
6.080%
€27.00
 
26.11.25 / Frankfurt WKN: A3EFB5 / Name: Relief Therapeutics Holding / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Relief Therapeutics Holding AG Stock

A very strong showing by Relief Therapeutics Holding AG today, with an increase of €0.17 (6.080%) compared to yesterday's price.
The community is currently still undecided about Relief Therapeutics Holding AG with 1 Buy predictions and 0 Sell predictions.
With a target price of 27 € there is potential for a 837.5% increase which would mean more than doubling the current price of 2.88 € for Relief Therapeutics Holding AG.

Pros and Cons of Relief Therapeutics Holding AG in the next few years

Pros
?
C******** o* t** e**********
?
B****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

News

Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032